Bevacizumab-induced hypertension: Pathogenesis and management

BioDrugs

Volumn 25, Issue 3, 2011, Pages 159-169

  Syrigos, Kostas N ^a   Karapanagiotou, Eleni ^b   Boura, Paraskevi ^a   Manegold, Christian ^c   Harrington, Kevin ^d  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Adverse drug reactions; Bevacizumab; Cancer; Hypertension

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; NEBIVOLOL; NITRIC OXIDE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO; PLACENTAL GROWTH FACTOR; SILDENAFIL; SUNITINIB; TEMOZOLOMIDE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTIHYPERTENSIVE THERAPY; ANTINEOPLASTIC ACTIVITY; ARTERIAL PRESSURE; BLOOD PRESSURE MONITORING; BLOOD VESSEL TONE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; COLORECTAL CANCER; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TARGETING; DRUG USE; DRUG WITHDRAWAL; ESOPHAGEAL ADENOCARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; GLIOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY FAILURE; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PATHOGENESIS; PATHOPHYSIOLOGY; PERITONEUM CANCER; PREECLAMPSIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SOLID TUMOR; STEADY STATE; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE; VASOCONSTRICTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; GLIOBLASTOMA; HUMANS; HYPERTENSION; KIDNEY NEOPLASMS; LUNG NEOPLASMS; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79957793636     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11590180-000000000-00000     Document Type: Review

References (69)

1. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007 Apr; 25 (12): 1539-44 (Pubitemid 46733080)
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer paclitaxelcarboplatin alone or with bevacizumab for non-small-cell lung cancer.NEngl J Med 2004 Jun; 350 (23): 2335-42 (Pubitemid 38702844)
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.NEngl JMed 2006 Dec; 355 (24): 2542-50
4. FDA Center for Drug Evaluation and Research. Office director memo. BLA 125085 Avastin (bevacizumab). Withdraw memo: metastatic Breast Cancer Indication [online]. Available from URL: http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM237171.pdf [Accessed 2011 Jan 13]
5. European Medicines Agency SMH. European Medicines Agency completes its review of Avastin used in breast cancer [online]. Available from URL: http://.ema.europa.eu/docs/en-GB/document-library/Press-release/2010/12/ WC500099929.pdf [Accessed 2011 May 9]
6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003 Jun; 9 (6): 669-76 (Pubitemid 36749215)
7. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991 Jun; 266 (18): 11947-54
8. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000; 55: 15-35
9. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999 Jul; 77 (7): 527-43 (Pubitemid 29426311)
10. Keshet E, Ben-Sasson SA. Anticancer drug targets: approaching angiogenesis. J Clin Invest 1999 Dec; 104 (11): 1497-501 (Pubitemid 30002360)
11. Linderholm BK, Lindh B, Beckman L, et al. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer 2003 Dec; 4 (5): 340-7 (Pubitemid 38139589)
12. Sledge Jr GW. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol 2002 Jun; 29 (3 Suppl. 11): 104-10 (Pubitemid 34816072)
13. Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001 Jul; 61 (14): 5407-14 (Pubitemid 32694919)
14. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987 Jan; 235 (4787): 442-7 (Pubitemid 17009577)
15. Presta LG, Chen H, OConnor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997 Oct; 57 (20): 4593-9 (Pubitemid 27441066)
16. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000 Apr; 60 (8): 2178-89 (Pubitemid 30225181)
17. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006 May; 312 (5777): 1171-5 (Pubitemid 43801134)
18. Willett CG, Boucher Y, di TE, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004 Feb; 10 (2): 145-7 (Pubitemid 38524883)
19. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001 Sep; 7 (9): 987-9 (Pubitemid 32937367)
20. Willett CG, Duda DG, di TE, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009 Jun; 27 (18): 3020-6
21. Manegold C, Pawel von J, Zatloukal P, et al. Efficacy and safety results from BO 17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or reccurent non-squamous non-small cell lung cancer (NCSLC) [abstract]. Eur J Cancer Suppl 2007; 5 (4): 356
22. William Jr WN, Kies MS, Fossella FV, et al. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmallcell lung cancer. Cancer 2010 May; 116 (10): 2401-8
23. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. JClin Oncol 2009 Jul; 27 (20): 3284-9
24. Lilenbaum R, Raez L, Tseng J, et al. Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J Thorac Oncol 2008 May; 3 (5): 511-5 (Pubitemid 351630279)
25. Reynolds C, Barrera D, Jotte R, et al. Phase II trial of nanoparticle albuminbound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2009Dec; 4 (12): 1537-43
26. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 Dec; 357 (26): 2666-76
27. Smith IE, Pierga JY, Biganzoli L, et al. First-line bevacizumab plus taxanebased chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Ann Oncol 2011 Sep; 22 (3): 595-602
28. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010 Jul; 28 (20): 3239-47
29. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [abstract]. J Clin Oncol 2009; 27 (15s): 1005
30. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005 Feb; 23 (4): 792-9 (Pubitemid 46224178)
31. Perez EA, Hillman DW, Kugler JW, et al. North Central Cancer Treatment Group (NCCTG) NO432: phase II trial of docetaxel with capecitabine and bevacizumab as first line chemotherapy for patients with metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl. 1): 2069
32. Yang JC,Haworth L, Sherry RM, et al.Arandomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 Jul; 349 (5): 427-34 (Pubitemid 36910021)
33. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial. Lancet 2007 Dec; 370 (9605): 2103-11 (Pubitemid 350296300)
34. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009 Oct; 27 (28): 4733-40
35. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009 Feb; 27 (5): 740-5
36. Rivory LP. Irinotecan (CPT-11): a brief overview. Clin Exp Pharmacol Physiol 1996 Oct; 23 (10-11): 1000-4 (Pubitemid 26361730)
37. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006 Apr; 24 (12): 1898-903 (Pubitemid 46638989)
38. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006 Nov; 24 (33): 5201-6 (Pubitemid 46631363)
39. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). 2007 ASCO Annual Meeting Proceedings Part I [abstract]. J Clin Oncol 2007; 25 (18 Suppl.): 4508
40. Burger RA, SillMW,Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007 Nov; 25 (33): 5165-71 (Pubitemid 350237599)
41. Cannistra SA,Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007 Nov; 25 (33): 5180-6 (Pubitemid 350232248)
42. Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007 Feb; 49 (2): 186-93 (Pubitemid 46178407)
43. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001 Feb; 19 (3): 843-50 (Pubitemid 32119100)
44. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. JClin Oncol 2001 Feb; 19 (3): 851-6 (Pubitemid 32119101)
45. Maitland ML, Moshier K, Imperial J, et al. Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway [abstract]. J Clin Oncol 2006; 24 (Suppl. 18): 2035
46. Maitland ML, Ratain MJ. Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med 2006 Nov; 145 (9): 702-3 (Pubitemid 46768848)
47. Yang R, Thomas GR, Bunting S, et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 1996 Jun; 27 (6): 838-44 (Pubitemid 26000416)
48. Neagoe PE, Lemieux C, SiroisMG. Vascular endothelial growth factor (VEGF)- A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem 2005 Mar; 280 (11): 9904-12 (Pubitemid 40395838)
49. Henry TD, Rocha-Singh K, Isner JM, et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J 2001 Nov; 142 (5): 872-80 (Pubitemid 33016208)
50. Shen BQ, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinaseCsignaling pathway. J BiolChem 1999 Nov; 274 (46): 33057-63 (Pubitemid 129535347)
51. Steeghs N, Hovens M, Rabelink A. VEGFR-2 blockade in patients with solid tumours: mechanism of hypertension and effects on vascular function. J Clin Oncol 2006; 24 (18S)
52. Mourad JJ, des Guetz G, Debbabi H, et al. Blood pressure rise following angiogenesis inhibition by bevacizumab: a crucial role for microcirculation. Ann Oncol 2008 May; 19 (5): 927-34 (Pubitemid 351627309)
53. Izzedine H, Rixe O, Billemont B, et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 2007 Aug; 50 (2): 203-18 (Pubitemid 47095077)
54. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003 Apr; 278 (15): 12605-8 (Pubitemid 36800018)
55. Nadar SK, Karalis I, Al YE, et al. Plasmamarkers of angiogenesis in pregnancy induced hypertension. Thromb Haemost 2005 Nov; 94 (5): 1071-6 (Pubitemid 41645951)
56. Mancia G, De BG, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007 Sep; 25 (9): 1751-62 (Pubitemid 47356612)
57. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008 Jan; 358 (1): 95-7
58. European Society of Hypertension. The 2009 hypertension guidelines and author disclosures [online]. Available from URL: http://www.eshonline. org/Guidelines/ArterialHypertension/2009Guidelines.aspx [Accessed 2011 May 9]
59. Aronof WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. Epub 2011 Apr 25
60. Mir O, Coriat R, Ropert S, et al. Treatment of bevacizumab-induced hypertension by amlodipine. Invest New Drugs. Epub 2010 Sep
61. Bottiglieri S, Muluneh B, Sutphin S, et al. Blood pressure control in patients receiving bevacizumab in an outpatient cancer center. J Oncol Pharm Pract. Epub 2010 Sep 3
62. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009 May; 20 (5): 807-15
63. Mares JE,Worah S, Mathew SV, et al. Increased rates of hypertension (HTN) among patients with advanced carcinoid treated with bevacizumab. J Clin Oncol 2005; 23 (Suppl. 16): 4087
64. Sato Y, Sonoda H. The vasohibin family: a negative regulatory system of angiogenesis genetically programmed in endothelial cells. Arterioscler Thromb Vasc Biol 2007 Jan; 27 (1): 37-41 (Pubitemid 46360378)
65. BC Cancer Agency. BC Cancer Agency cancer management guidelines. Management guidelines of bevacizumab-related side effects [online]. Available from URL: http://www.bccancer.bc.ca/NR/rdonlyres/6D39414F-EC1A- 4BE2-9ACB-6DE017C9B4C4/19258/Managementforbevacizumabsideeffects- 1Dec06.pdf [Accessed 2011 Jan 10]
66. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 2006 Oct; 48 (4): 622-7 (Pubitemid 44843865)
67. Porta C, Paglino C, Imarisio I, et al. Uncovering Pandoras vase: the growing problem of new toxicities from novel anticancer agents: the case of sorafenib and sunitinib. Clin Exp Med 2007 Dec; 7 (4): 127-34
68. Ranpura V, Pulipati B, Chu D, et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010 May; 23 (5): 460-8
69. Elaraj DM, White DE, Steinberg SM, et al. A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J Immunother 2004 Jul; 27 (4): 259-64 (Pubitemid 38833321)